Published on 13 Mar 2023 on Bloomberg via Yahoo Finance
(Bloomberg) -- Pfizer Inc. is purchasing cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, using the biggest deal of the year to set its course out of the pandemic and back into mainstream pharma.
Most Read from Bloomberg
In this article, we will take a look at the 10 biotech stocks with huge potential. To skip our an...
Seagen Inc. Sale Marks Notable Portfolio Change for PRIMECAP Management (Trades, Portfolio) PRIME...
In this article, we discuss the 12 best stocks to buy on Robinhood for beginners. If you want to ...
After the FOMC meeting on December 13th, the Federal Reserve signaled the end of the bias toward...
In this article, we will take a look at the 11 most promising biotech stocks to buy according to ...
Pfizer, Inc. PFE shares are trading higher Friday. The stock remains down by more than 11% over t...
The Business Journal’s List of highest-paid public company CEOs has a few new names this year,...
The pharmaceutical giant’s stock has plunged 49% so far this year, on track for its worst year on...
The stock market witnessed a notable surge today, with the Dow Jones rising 0.43% to 37,248.35 an...
Major U.S. indices were in the green on Wednesday with the Dow Jones rising 1.4% to 37,090.24, th...
Copyright Statfolio @ 2025